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On April 8, 2019, Maryland’s General Assem-bly passed a law creating a prescription-drug affordability board to help the state regulate 
drug prices. This policy, which took effect on July 1, 
2019, requires drug manufacturers 
to justify high prices or price 
spikes for both patented and ge-
neric drugs. If the board rejects 
a manufacturer’s explanation for a 
pricing decision, it can, with the 
approval of the state legislature, 
set a lower price for the drug.
This approach represents a 
more direct attack on prescription-
drug prices than the wave of 45 
cost-control bills passed by 28 
states in 2018. Such efforts fo-
cused largely on regulating and 
licensing pharmacy benefit man-
agers and prohibiting them from 
keeping pharmacists from inform-
ing patients about lower-priced op-
tions.1 Similarly, California’s drug-
transparency law, which went 
into effect in 2018, was hailed as 
one of the most transformative 
pieces of health legislation in the 
country. But that law requires 
drug makers only to provide no-
tice before they raise prices above 
certain thresholds; it doesn’t di-
rectly regulate prices.
The Maryland law, and the 
model law on which it is based, 
go further by permitting payment 
limits. Such a mechanism is un-
common in the United States, 
although precedents exist, includ-
ing policies permitting state boards 
to cap the cost of electricity, car-
insurance premiums, and hospi-
tal rates — domains in which 
policymakers have found that 
competition alone may not pro-
tect the public from extremely 
high prices. From a global per-
spective, many countries limit 
how much they pay for prescrip-
tion drugs by negotiating prices 
and implementing national for-
mularies and price ceilings.2
Maryland’s law was originally 
intended to apply to all payers, 
including commercial plans, but 
it was amended just before pas-
sage to apply only to health plans 
that serve employees of the state 
government and of county and 
city governments. Although this 
change dramatically narrows the 
scope of the law, it helped limit 
political opposition and may im-
prove the law’s prospects in the 
courts.
Maryland has attempted to reg-
ulate drug prices before. In 2017, 
the state passed the Anti–Price-
Gouging Act to prohibit uncon-
scionable price increases, but the 
federal Fourth Circuit Court of 
Appeals struck down the law as 
unconstitutional on the grounds 
that it interfered with interstate 
commerce, which is the exclusive 
domain of the federal govern-
ment.3 In early 2019, the U.S. Su-
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preme Court refused to hear the 
state’s appeal, thus sealing the 
law’s fate. Unlike the price-goug-
ing legislation, the new Maryland 
law doesn’t regulate commerce — 
it simply allows the state to decide 
how it spends its own money. 
State lawmakers thus avoided the 
legal problems that plagued the 
prior bill.
We believe that the new law is 
a harbinger of what’s to come in 
drug-pricing legislation. During 
the 2019 legislative session, eight 
additional states introduced bills 
that would create drug-cost com-
missions. Legislation is pending 
in half these states, failed in three 
states, and recently passed in 
Maine. Maine’s affordability board 
act was part of a four-bill prescrip-
tion-drug–reform package and is 
less detailed in its approach than 
the Maryland law. Like Maryland, 
Maine limits its board’s scope to 
state, county, and local govern-
ment health plans.
The Maryland law and other 
state bills call for a cost review 
only when prices or price increas-
es for certain drugs exceed spec-
ified thresholds. They create 
boards or commissions of five to 
nine people who would range 
from elected officials to members 
of the public and establish larger 
advisory or stakeholder councils 
composed of patient representa-
tives, payers, providers, and phar-
maceutical manufacturers.
Most state bills trigger board 
review for patented drugs when 
drugs enter the market with a 
wholesale acquisition cost of at 
least $30,000 per year or treat-
ment course or undergo a price 
hike of at least 10%, $10,000, or 
$3,000 within 1 year, depending 
on the state. For generic medica-
tions, board review is generally 
triggered when a drug costs 
$3,000 or more per year or has 
increased in price by 25% or 
$300 for a 30-day supply within a 
1-year period. Maryland is one of 
a minority of states that use lower 
thresholds.
There is an important third 
trigger for review that the Mary-
land law and most state bills in-
clude, which functions as a catch-
all. Beyond the specified price 
triggers, a board can review any 
prescription drug when it deter-
mines that the drug creates af-
fordability challenges for the state 
health care system and patients.
The pending state bills gener-
ally grant affordability boards 
broad authority to establish new 
reimbursement levels for reviewed 
drugs after determining that a 
given price or price increase is 
justifiable using information pro-
vided by the manufacturer, in-
cluding information on research 
and development costs and prices 
elsewhere. Maryland’s law, how-
ever, takes a more conservative 
approach. Maryland’s board re-
ports its determinations to the 
state’s legislative policy commit-
tee, and the committee then has 
45 days to approve the board’s 
proposed reimbursement rate. If it 
doesn’t approve the rate, the board 
then submits its proposal to the 
governor and state attorney gen-
eral. Maryland’s board cannot set 
a payment limit without approval 
of the legislative policy commit-
tee or the governor and state at-
torney general.4 Drug manufac-
tures are required to accept the 
price set by the board in order to 
sell the drug in question to state, 
county, and local government 
plans operating in Maryland.
Similarly, Maine’s board isn’t 
authorized to set spending caps; 
rather, it provides recommenda-
tions on spending targets for 
drugs to the joint standing com-
mittee of the legislature. These 
limited powers call into question 
how effective affordability boards 
will be at reducing costs, even for 
public payers. They also reflect a 
concern among some state legis-
lators — which the drug industry 
has reinforced — that such boards 
may ultimately reduce access to 
certain cutting-edge drugs. Mary-
land also limits its board’s author-
ity to regulate the prices of drugs 
that are in short supply, which 
therefore preserves access to es-
sential medications, regardless 
of cost.
Such provisions reflect the fact 
that Maryland has relatively little 
bargaining power; companies 
could simply walk away from the 
market, rather than set a prece-
dent for other payers by selling 
certain drugs at prices below cur-
rent levels. States may need to 
act collectively to simultaneously 
drive down prices and ensure ac-
cess to drugs. The current con-
solidated state of the pharmaceu-
tical industry, in which many 
drug makers face little or no di-
rect competition, exploits the frag-
mentation of the states.
Still, we believe that such ef-
forts by state legislators repre-
sent laudable experiments to ad-
dress a recognized problem. State 
drug-pricing reform efforts are 
building on each other; many of 
the bills proposing drug-cost re-
view boards also incorporate ele-
ments from price-transparency 
laws. For example, under Mary-
land’s law and the bills intro-
duced in other states, drug man-
ufacturers have the opportunity to 
explain prices or price increases 
as part of the review process. 
Price-transparency laws have thus 
far withstood legal challenges 
from the drug industry claiming 
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that they interfere with interstate 
commerce and violate the First 
and Fourteenth Amendments.5 
California’s law has reportedly 
had some success, as drug com-
panies have decided to rescind 
or reduce previously announced 
price increases for health plans 
in that state. Establishing afford-
ability boards may be a natural 
next step that more states take to 
exert a stronger in-
f luence over price 
spikes and still sur-
vive legal challenges.
The challenge facing any state-
level effort will be to achieve the 
kind of scale necessary to affect 
an industry that manufactures 
more than 4 billion prescriptions’ 
worth of drugs each year for the 
United States alone. These new 
approaches are unlikely to be a 
substitute for a federal solution 
that alters the fundamental mar-
ket factors responsible for driving 
up drug prices.
Disclosure forms provided by the authors 
are available at NEJM.org.
From the University of Arizona James E. 
Rogers College of Law. 
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How Peer Evaluation Could Enhance the Referral Process
Colleagues Unknown — How Peer Evaluation Could Enhance 
the Referral Process
Gregory E. Brisson, M.D. 
My email was written in good faith, but still the subject 
was delicate. I was looking for a 
specialist who would be a good 
fit for my patient, an anxious 
gentleman who required extra 
time at office visits to get an-
swers to his many questions. He 
had seen my go-to consultant in 
this specialty, a seasoned physi-
cian with a gentle bedside man-
ner. That visit had not gone well. 
Whatever the reasons, he wanted 
a new doctor. Rather than blindly 
referring him to any available phy-
sician in the division, I emailed a 
cadre of colleagues to get their 
recommendations.
They didn’t have any. Their 
experience with the division in 
question was as limited as mine. 
I considered resending the email 
to the entire general-medicine 
mailing list, but I had concerns 
about maintaining confidential-
ity, and physicians’ mailboxes are 
already inundated. Instead, I con-
tacted a specialist who was new 
to the system. She could see the 
patient the next day, though he 
would have to drive an hour to the 
city where her clinic was located. 
He agreed. With the expectations 
of both parties managed, the 
visit went smoothly.
Finding patient-centered solu-
tions has always been one of the 
challenges and rewards of clini-
cal medicine, but stories like this 
one are becoming routine. I reg-
ularly receive emails from peers 
who need help navigating the 
system. Colleagues at other insti-
tutions describe similar experi-
ences. These observations raise 
questions about how doctors re-
fer and shed light on the reality 
that generalists and specialists 
increasingly don’t know each 
other. It’s now the norm for U.S. 
physicians to work in large groups 
— networks that can span coun-
ties or cross state lines.1 In such 
systems, there’s little opportunity 
for interaction among colleagues.
It wasn’t always this way. Ear-
lier in my career, I knew most of 
the doctors at my hospital. I was 
generally aware of who was kind, 
curious, and a good collaborator 
— qualities I value in consultants. 
When I made a referral, it was 
usually to someone I knew first-
hand whom I could trust. That 
started to change in the past 
decade.
The group I work for merged 
with several hospitals and grew 
from hundreds of physicians to 
thousands — I can’t possibly 
know them all, no matter how 
many meet-and-greet socials I at-
tend. Hospitalist programs in-
f lamed the problem by discon-
necting generalists from hospitals, 
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